Single-cell RNA sequencing reveals enhanced antitumor immunity after combined application of PD-1 inhibitor and Shenmai injection in non-small cell lung cancer

[1]  I. Soubeyran,et al.  Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies , 2022, Journal for ImmunoTherapy of Cancer.

[2]  D. Yu,et al.  Revealing the transcriptional heterogeneity of organ‐specific metastasis in human gastric cancer using single‐cell RNA Sequencing , 2022, Clinical and translational medicine.

[3]  Hao Li,et al.  Single‐cell RNA sequencing reveals the multi‐cellular ecosystem in different radiological components of pulmonary part‐solid nodules , 2022, Clinical and translational medicine.

[4]  B. Nabet,et al.  Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. , 2022, Cancer cell.

[5]  Ye Tian,et al.  Single-Cell RNA Sequencing in Lung Cancer: Revealing Phenotype Shaping of Stromal Cells in the Microenvironment , 2022, Frontiers in Immunology.

[6]  M. Hellmann,et al.  First-Line Immunotherapy for Non-Small-Cell Lung Cancer. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Y. Tao,et al.  What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy? , 2021, Frontiers in Immunology.

[8]  T. Jacks,et al.  Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platform , 2021, bioRxiv.

[9]  Qianhui Xu,et al.  Single-cell RNA transcriptome reveals the intra-tumoral heterogeneity and regulators underlying tumor progression in metastatic pancreatic ductal adenocarcinoma , 2021, Cell death discovery.

[10]  Xiaomin Zhong,et al.  Roles of GFPT2 Expression Levels on the Prognosis and Tumor Microenvironment of Colon Cancer , 2021, Frontiers in Oncology.

[11]  Wei Zhou,et al.  A Multidimensional Bayesian Network Meta-Analysis of Chinese Herbal Injections for Treating Non-small Cell Lung Cancer With Gemcitabine and Cisplatin , 2021, Frontiers in Pharmacology.

[12]  Dong Wang,et al.  The S100 protein family in lung cancer. , 2021, Clinica chimica acta; international journal of clinical chemistry.

[13]  Y. Lévy,et al.  TLR9- and CD40-Targeting Vaccination Promotes Human B Cell Maturation and IgG Induction via pDC-Dependent Mechanisms in Humanized Mice , 2021, Frontiers in Immunology.

[14]  J Zhang,et al.  Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer , 2021, Nature Communications.

[15]  Xiangwei Lv,et al.  Efficacy and Safety of a Combination of Shenmai Injection plus Chemotherapy for the Treatment of Lung Cancer: A Meta-Analysis , 2021, Evidence-based complementary and alternative medicine : eCAM.

[16]  R. Braren,et al.  BCL3 couples cancer stem cell enrichment with pancreatic cancer molecular subtypes. , 2021, Gastroenterology.

[17]  Jun Zhang,et al.  The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma , 2021, Molecules.

[18]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[19]  Xiaoyun Mao,et al.  ATF4 promotes lung cancer cell proliferation and invasion partially through regulating Wnt/β-catenin signaling , 2021, International journal of medical sciences.

[20]  Seon-Hee Oh,et al.  Salinomycin suppresses TGF-β1-induced EMT by down-regulating MMP-2 and MMP-9 via the AMPK/SIRT1 pathway in non-small cell lung cancer , 2021, International journal of medical sciences.

[21]  Guangji Wang,et al.  Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy. , 2020, Journal of ethnopharmacology.

[22]  N. E. Thomford,et al.  Cancer Stem Cell Markers in Relation to Patient Survival Outcomes: Lessons for Integrative Diagnostics and Next-Generation Anticancer Drug Development. , 2020, Omics : a journal of integrative biology.

[23]  Henry W. Long,et al.  Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer , 2020, Cancer Research.

[24]  Yulei N. Wang,et al.  Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities , 2020, Frontiers in Immunology.

[25]  P. Lu,et al.  Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations , 2020, Oncogene.

[26]  D. Ettinger,et al.  Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. , 2020, JAMA oncology.

[27]  I. Baranowska-Bosiacka,et al.  CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands , 2020, International journal of molecular sciences.

[28]  Fanshuang Zhang,et al.  Lung Cancer in People's Republic of China. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  Jin-jian Lu,et al.  Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. , 2020, Pharmacology & therapeutics.

[30]  E. Jung,et al.  ERH overexpression is associated with decreased cell migration and invasion and a good prognosis in gastric cancer , 2020, Translational cancer research.

[31]  I. Corre,et al.  Endothelial-to-Mesenchymal Transition in Cancer , 2020, Frontiers in Cell and Developmental Biology.

[32]  Yi-Ching Wang,et al.  Dysregulated Kras/YY1/ZNF322A/Shh transcriptional axis enhances neo-angiogenesis to promote lung cancer progression , 2020, Theranostics.

[33]  A. Ianaro,et al.  The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion , 2020, Frontiers in Immunology.

[34]  Yu Chen,et al.  SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges , 2020, Journal of Hematology & Oncology.

[35]  M. Smyth,et al.  The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies , 2020, Nature Immunology.

[36]  Chen Wang,et al.  Targeting tumor-associated macrophages and granulocytic-myeloid-derived suppressor cells augments pd-1 blockade in cholangiocarcinoma. , 2020, The Journal of clinical investigation.

[37]  Xueda Hu,et al.  Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer , 2020, Cancer Immunology, Immunotherapy.

[38]  N. Iwanami,et al.  Lymphocyte-Specific Function of the DNA Polymerase Epsilon Subunit Pole3 Revealed by Neomorphic Alleles. , 2020, Cell reports.

[39]  T. Cheng,et al.  Single-cell transcriptome profiling reveals neutrophil heterogeneity in homeostasis and infection , 2020, Nature Immunology.

[40]  Jung-Il Lee,et al.  Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma , 2020, Nature Communications.

[41]  Y. Yarden,et al.  The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy , 2020, Molecular Cancer.

[42]  A. Dietz,et al.  Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations. , 2020, Thyroid : official journal of the American Thyroid Association.

[43]  Zhou Wang,et al.  Knockdown of GINS2 inhibits proliferation and promotes apoptosis through the p53/GADD45A pathway in non-small-cell lung cancer , 2020, Bioscience reports.

[44]  S. Novello,et al.  Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Yixin Li,et al.  Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[46]  V. Hervieu,et al.  Loss of Tenascin-X expression during tumor progression: A new pan-cancer marker , 2020, Matrix biology plus.

[47]  Mona,et al.  Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders. , 2019, Immunobiology.

[48]  Charles H. Yoon,et al.  Discovery of specialized NK cell populations infiltrating human melanoma metastases. , 2019, JCI insight.

[49]  Hanlee P. Ji,et al.  Single-Cell Genomic Characterization Reveals the Cellular Reprogramming of the Gastric Tumor Microenvironment , 2019, Clinical Cancer Research.

[50]  I. Melero,et al.  Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.

[51]  A. Lamort,et al.  Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight , 2019, Cells.

[52]  N. Reinmuth,et al.  Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[53]  C. Watzl,et al.  Mechanisms of natural killer cell‐mediated cellular cytotoxicity , 2019, Journal of leukocyte biology.

[54]  O. Bischof,et al.  AP-1 Imprints a Reversible Transcriptional Program of Senescent Cells , 2019, bioRxiv.

[55]  Alireza Hadj Khodabakhshi,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[56]  E. Ruiz-Pesini,et al.  Oxidative phosphorylation inducers fight pathological angiogenesis. , 2019, Drug discovery today.

[57]  Wenying Zhao,et al.  An TRIM59‐CDK6 axis regulates growth and metastasis of lung cancer , 2018, Journal of cellular and molecular medicine.

[58]  Michael J. T. Stubbington,et al.  Single-cell reconstruction of the early maternal–fetal interface in humans , 2018, Nature.

[59]  Douglas A. Lauffenburger,et al.  Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics , 2018, Cell reports.

[60]  A. Morokoff,et al.  VDAC2 enables BAX to mediate apoptosis and limit tumor development , 2018, Nature Communications.

[61]  Jianjun Li,et al.  Shenmai injection improves the postoperative immune function of papillary thyroid carcinoma patients by inhibiting differentiation into Treg cells via miR‐103/GPER1 axis , 2018, Drug development research.

[62]  Guo-Cheng Yuan,et al.  Revealing the Critical Regulators of Cell Identity in the Mouse Cell Atlas , 2018, bioRxiv.

[63]  M. McBurney,et al.  Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade , 2018, The Journal of clinical investigation.

[64]  P. Carmeliet,et al.  Phenotype molding of stromal cells in the lung tumor microenvironment , 2018, Nature Medicine.

[65]  Boxi Kang,et al.  Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing , 2018, Nature Medicine.

[66]  Ming Zhou,et al.  NEAT1 acts as an inducer of cancer stem cell‐like phenotypes in NSCLC by inhibiting EGCG‐upregulated CTR1 , 2018, Journal of cellular physiology.

[67]  N. Karin.  Chemokines and cancer: new immune checkpoints for cancer therapy. , 2018, Current opinion in immunology.

[68]  Zeyi Liu,et al.  Long non-coding RNA XIST promotes TGF-β-induced epithelial-mesenchymal transition by regulating miR-367/141-ZEB2 axis in non-small-cell lung cancer. , 2018, Cancer letters.

[69]  P. Chow,et al.  Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy , 2018, Gut.

[70]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[71]  J. Banchereau,et al.  Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[72]  J. Aerts,et al.  SCENIC: Single-cell regulatory network inference and clustering , 2017, Nature Methods.

[73]  Fen Pei,et al.  Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer , 2017, International journal of molecular sciences.

[74]  M. Lai,et al.  Differential Expression Pattern of THBS1 and THBS2 in Lung Cancer: Clinical Outcome and a Systematic-Analysis of Microarray Databases , 2016, PloS one.

[75]  S. Finn,et al.  Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. , 2016, Pharmacology & therapeutics.

[76]  Pei Su,et al.  EML4-ALK induces epithelial-mesenchymal transition consistent with cancer stem cell properties in H1299 non-small cell lung cancer cells. , 2015, Biochemical and biophysical research communications.

[77]  G. Cook,et al.  Licensed human natural killer cells aid dendritic cell maturation via TNFSF14/LIGHT , 2014, Proceedings of the National Academy of Sciences.

[78]  Guo-Qing Zheng,et al.  An Overview of Systematic Reviews of Shenmai Injection for Healthcare , 2014, Evidence-based complementary and alternative medicine : eCAM.

[79]  D. Radisky,et al.  Triggering the landslide: The tumor-promotional effects of myofibroblasts. , 2013, Experimental cell research.

[80]  M. Takagi,et al.  Regulation of p53 Translation and Induction after DNA Damage by Ribosomal Protein L26 and Nucleolin , 2005, Cell.

[81]  H. Goike,et al.  Clinical utility of cytokeratins as tumor markers. , 2004, Clinical biochemistry.

[82]  Caifeng Xie,et al.  COMMD9 promotes TFDP1/E2F1 transcriptional activity via interaction with TFDP1 in non-small cell lung cancer. , 2017, Cellular signalling.

[83]  Lian-xin Wang,et al.  [Literature analysis of tumor treatment by Shenmai injection]. , 2012, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.

[84]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..